Financials

	2022	2023
Net sales	54.13M 47.54M 44.21M 40.57M 76.23M 5.21B 77.4M 525M 205M 2.56B 203M 199M 8.86B	80.75M 70.93M 65.96M 60.53M 114M 7.78B 115M 783M 306M 3.82B 303M 297M 13.22B
Net income	-18.11M -15.9M -14.79M -13.57M -25.5M -1.74B -25.89M -176M -68.61M -857M -67.97M -66.51M -2.96B	-20.13M -17.68M -16.44M -15.09M -28.35M -1.94B -28.79M -195M -76.29M -953M -75.58M -73.95M -3.3B
Net Debt	42.09M 36.97M 34.38M 31.55M 59.27M 4.05B 60.19M 408M 159M 1.99B 158M 155M 6.89B	55.34M 48.61M 45.2M 41.48M 77.94M 5.33B 79.14M 537M 210M 2.62B 208M 203M 9.06B

* Estimated data More financial data

Company Profile

Alimera Sciences, Inc. is a global pharmaceutical company. The Company is focused on helping patients, physicians and partners concerned with retinal health and maintaining better vision longer.

Employees

157

Sector

Pharmaceuticals

More about the company

Income Statement and Estimates

More financial data

Market Closed - Nasdaq Other stock markets 00:00:00 14/09/2024 +04			5-day change	1st Jan Change
5.540 ^USD	-0.18%		-.--%	-

16/09/24	ANI Pharmaceuticals Completes Purchase of Alimera Sciences, Sees 'Substantially Higher' Earnings After Deal	MT
16/09/24	Alimera Sciences, Inc.(NasdaqGM:ALIM) dropped from NASDAQ Composite Index	CI

Market Cap	301M 265M 246M 226M 424M 29.01B 431M 2.92B 1.14B 14.26B 1.13B 1.11B 49.32B	P/E 2022	-1.05x	P/E 2023	-5.16x
Enterprise Value	357M 313M 291M 267M 502M 34.34B 510M 3.46B 1.35B 16.88B 1.34B 1.31B 58.38B	EV / Sales 2022	1.13x	EV / Sales 2023	3.49x
Free-Float	94.65%	Yield 2022 *	-	Yield 2023	-

16/09/24	ANI Pharmaceuticals Completes Purchase of Alimera Sciences, Sees 'Substantially Higher' Earnings After Deal	MT
16/09/24	Alimera Sciences, Inc.(NasdaqGM:ALIM) dropped from NASDAQ Composite Index	CI
16/09/24	ANI Pharmaceuticals, Inc. completed the acquisition of Alimera Sciences, Inc. from Caligan Partners Master Fund LP and Caligan Partners Master Fund LP, managed by Caligan Partners, LP and others.	CI
11/09/24	Exchange-Traded Funds, Equity Futures Lower Pre-Bell Wednesday as Looming CPI Data Likely to Provide Rate-Cut Clues	MT
11/09/24	ANI Pharmaceuticals, Alimera Sciences to Close Merger Next Week	MT
10/09/24	Alimera Sciences Sues ANI Pharmaceuticals for Delays in Merger Close	MT
10/09/24	Alimera Sciences, Inc.(NasdaqGM:ALIM) dropped from S&P TMI Index	CI
06/08/24	Alimera Sciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024	CI
17/07/24	Processa Pharmaceuticals Appoints Russell Skibsted as CFO	MT
01/07/24	Alimera Sciences, Inc.(NasdaqGM:ALIM) added to Russell Small Cap Comp Value Index	CI
01/07/24	Alimera Sciences, Inc.(NasdaqGM:ALIM) added to Russell Small Cap Completeness Index	CI
01/07/24	Alimera Sciences, Inc.(NasdaqGM:ALIM) added to Russell 2000 Index	CI
01/07/24	Alimera Sciences, Inc.(NasdaqGM:ALIM) added to Russell 3000E Index	CI

25/06/24	Maxim Downgrades Alimera Sciences to Hold From Buy	MT
25/06/24	Alliance Global Partners Downgrades Alimera Sciences to Neutral From Buy, Adjusts Price Target to $5.50 From $8	MT
25/06/24	Craig-Hallum Downgrades Alimera Sciences to Hold From Buy, Price Target is $5.50	MT
25/06/24	HC Wainwright Downgrades Alimera Sciences to Neutral From Buy, Price Target is $6	MT
25/03/24	Maxim Initiates Alimera Sciences at Buy Rating With $10 Price Target	MT

Alimera Sciences, Inc. Stock

Stocks

ALIM

US0162592028

Pharmaceuticals

Valuation: Alimera Sciences, Inc.

Latest news : Alimera Sciences, Inc.

Analysts' recommendations: Alimera Sciences, Inc.

Press Releases: Alimera Sciences, Inc.

News in other languages: Alimera Sciences, Inc.

Quotes and Performance

Course Extremes

Managers and Directors: Alimera Sciences, Inc.

Latest insider transactions

Biopharmaceuticals

Financials

Company Profile

Income Statement and Estimates

16/09/24	ANI Pharmaceuticals, Inc. Completes Acquisition of Alimera Sciences	AQ
11/09/24	ANI Pharmaceuticals and Alimera Sciences Announce Closing Date of Merger	BU
11/09/24	ANI Pharmaceuticals and Alimera Sciences Announce Closing Date of Merger	AQ
10/09/24	ANI Pharmaceuticals Provides Update on Closing of Acquisition of Alimera Sciences	AQ
10/09/24	Alimera Sciences Takes Legal Action Against ANI Pharmaceuticals to Enforce Merger Agreement	BU

Manager	Title	Age	Since
Elliot Maltz DFI	Director of Finance/CFO	41	02/01/2024
Jason Werner COO	Chief Operating Officer	48	02/10/2023
Laura Cegala HRO	Human Resources Officer	-	-

Date	Insider	Type	Main position	Quantity	% Market Cap.
16/09/24	Margaret Pax	Issuer sale	Director	36,713	0.0675%
16/09/24	Jason Werner	Issuer sale	Chief Operating Officer	477,721	0.8784%
16/09/24	Richard Eiswirth	Issuer sale	President and CEO	2,371,189	4.3601%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ALIMERA SCIENCES, INC.	-0.18%	-.--%	-.--%	+57.83%	287M
REGENERON PHARMACEUTICALS, INC.	+0.63%	-3.06%	+16.18%	-9.78%	66.32B
UCB	+1.23%	+3.49%	+38.32%	+199.93%	52.6B
SAMSUNG BIOLOGICS CO.,LTD.	+10.08%	+51.80%	+51.80%	+51.80%	43.27B
CSL LIMITED	-1.32%	-6.34%	-56.98%	-57.24%	38.64B
BIOGEN INC.	+0.78%	-1.84%	+52.49%	-27.01%	29.62B
INCYTE CORPORATION	+0.84%	+0.36%	+66.93%	+85.42%	23.31B
MODERNA, INC.	-5.17%	-12.54%	+58.98%	-56.04%	22.62B
INNOVENT BIOLOGICS, INC.	-1.21%	-4.51%	+2.22%	+174.24%	20.22B
SWEDISH ORPHAN BIOVITRUM AB	-0.22%	-1.80%	+66.21%	+119.48%	16.29B
Average	+0.56%	-1.20%	+29.62%	+53.86%	31.32B
Weighted average by Cap.	+1.25%	-0.65%	+27.78%	+48.87%

3 years	2.61	5.65
5 years	1.3	9.79
10 years	0	36